A detailed history of Jane Street Group, LLC transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 58,760 shares of AQST stock, worth $179,218. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,760
Previous 126,826 53.67%
Holding current value
$179,218
Previous $329,000 11.25%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.4 - $5.09 $163,358 - $346,455
-68,066 Reduced 53.67%
58,760 $292,000
Q2 2024

Aug 14, 2024

SELL
$2.31 - $4.5 $314,885 - $613,413
-136,314 Reduced 51.8%
126,826 $329,000
Q1 2024

May 15, 2024

BUY
$2.01 - $6.09 $215,180 - $651,964
107,055 Added 68.59%
263,140 $1.12 Million
Q4 2023

Feb 14, 2024

BUY
$1.29 - $2.47 $201,349 - $385,529
156,085 New
156,085 $315,000
Q1 2023

May 15, 2023

BUY
$0.72 - $1.15 $16,869 - $26,944
23,430 New
23,430 $26,000
Q3 2021

Nov 16, 2021

SELL
$3.25 - $4.66 $42,571 - $61,041
-13,099 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$3.29 - $5.21 $858 - $1,359
-261 Reduced 1.95%
13,099 $52,000
Q1 2021

May 18, 2021

SELL
$4.17 - $6.73 $180,944 - $292,028
-43,392 Reduced 76.46%
13,360 $69,000
Q4 2020

Feb 17, 2021

SELL
$4.65 - $7.79 $29,694 - $49,746
-6,386 Reduced 10.11%
56,752 $304,000
Q3 2020

Nov 17, 2020

BUY
$4.12 - $9.09 $214,499 - $473,252
52,063 Added 470.09%
63,138 $306,000
Q2 2020

Aug 17, 2020

BUY
$1.84 - $6.44 $20,378 - $71,323
11,075 New
11,075 $54,000
Q3 2019

Nov 14, 2019

SELL
$3.04 - $4.91 $96,054 - $155,141
-31,597 Closed
0 $0
Q2 2019

Aug 15, 2019

BUY
$3.72 - $6.95 $117,540 - $219,599
31,597 New
31,597 $133,000

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $163M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.